GB2269382A - Pharmaceutical xanthone derivatives - Google Patents

Pharmaceutical xanthone derivatives

Info

Publication number
GB2269382A
GB2269382A GB9319494A GB9319494A GB2269382A GB 2269382 A GB2269382 A GB 2269382A GB 9319494 A GB9319494 A GB 9319494A GB 9319494 A GB9319494 A GB 9319494A GB 2269382 A GB2269382 A GB 2269382A
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical
xanthone derivatives
cooh
xanthone
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB9319494A
Other versions
GB9319494D0 (en
GB2269382B (en
Inventor
Peter John Hylands
Stephen Keith Wrigley
Glenda Louise Chandler
Mark Anthony David Collins
Frances Fox
Michael Moore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenova Ltd
Original Assignee
Xenova Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919106184A external-priority patent/GB9106184D0/en
Priority claimed from GB919111736A external-priority patent/GB9111736D0/en
Priority claimed from GB919116593A external-priority patent/GB9116593D0/en
Priority claimed from GB929205301A external-priority patent/GB9205301D0/en
Application filed by Xenova Ltd filed Critical Xenova Ltd
Priority to GB9319494A priority Critical patent/GB2269382B/en
Publication of GB9319494D0 publication Critical patent/GB9319494D0/en
Publication of GB2269382A publication Critical patent/GB2269382A/en
Application granted granted Critical
Publication of GB2269382B publication Critical patent/GB2269382B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C07D311/84—Xanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C07D311/86—Oxygen atoms, e.g. xanthones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/162—Heterorings having oxygen atoms as the only ring heteroatoms, e.g. Lasalocid

Abstract

A xanthone derivative of formula (1), wherein ---- is a single bond and R is -COOH or ---- is a double bond and R is H or COOH, and pharmaceutically and veterinarily acceptable salts, esters and ethers thereof, are useful as CD4 binding agents and inhibitors of protein kinase C and collagenase.
GB9319494A 1991-03-22 1993-09-21 Pharmaceutical compounds Expired - Fee Related GB2269382B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9319494A GB2269382B (en) 1991-03-22 1993-09-21 Pharmaceutical compounds

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB919106184A GB9106184D0 (en) 1991-03-22 1991-03-22 Pharmaceutical compound
GB919111736A GB9111736D0 (en) 1991-05-31 1991-05-31 Pharmaceutical compound
GB919116593A GB9116593D0 (en) 1991-08-01 1991-08-01 Pharmaceutical compounds
GB929205301A GB9205301D0 (en) 1992-03-11 1992-03-11 Pharmaceutical compound
PCT/GB1992/000526 WO1992016517A1 (en) 1991-03-22 1992-03-23 Pharmaceutical xanthone derivatives
GB9319494A GB2269382B (en) 1991-03-22 1993-09-21 Pharmaceutical compounds

Publications (3)

Publication Number Publication Date
GB9319494D0 GB9319494D0 (en) 1993-12-01
GB2269382A true GB2269382A (en) 1994-02-09
GB2269382B GB2269382B (en) 1995-02-08

Family

ID=27450647

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9319494A Expired - Fee Related GB2269382B (en) 1991-03-22 1993-09-21 Pharmaceutical compounds

Country Status (4)

Country Link
EP (1) EP0580609A1 (en)
JP (1) JPH06506202A (en)
GB (1) GB2269382B (en)
WO (1) WO1992016517A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018173A2 (en) * 1992-03-11 1993-09-16 Xenova Limited Cd4 binding agents and inhibitors of collagenase and protein kinase c
SI0817627T1 (en) * 1993-12-23 2005-08-31 Lilly Co Eli
GB9601042D0 (en) * 1996-01-17 1996-03-20 Smithkline Beecham Plc Medical use
GB9414157D0 (en) * 1994-07-13 1994-08-31 Smithkline Beecham Plc Medical use
JPH11512708A (en) 1995-09-11 1999-11-02 オステオアルスリィティス サイエンシズ，インコーポレイテッド Protein tyrosine kinase inhibitors for treating osteoarthritis
EP0795554A3 (en) * 1996-03-05 1998-01-28 Takeda Chemical Industries, Ltd. (Oxo-)xanthene derivatives, their preparation and their use as immunomodulators
AU5666800A (en) * 1999-06-22 2001-01-09 Mount Sinai Hospital Corporation Difuropyrone derivatives
JP4975231B2 (en) 2000-07-28 2012-07-11 大日本住友製薬株式会社 Nerve regeneration promoter containing semaphorin inhibitor as active ingredient
EP1351946A2 (en) 2000-09-01 2003-10-15 Icos Corporation Materials and methods to potentiate cancer treatment
WO2003062440A1 (en) * 2002-01-21 2003-07-31 Sumitomo Pharmaceuticals Co., Ltd. Xanthone derivative
EP1475382B1 (en) * 2002-01-24 2008-12-10 Dainippon Sumitomo Pharma Co., Ltd. Compounds as semaphorin inhibitors
US8404681B2 (en) 2003-03-24 2013-03-26 Luitpold Pharmaceuticals, Inc. Xanthones, thioxanthones and acridinones as DNA-PK inhibitors
ATE555783T1 (en) * 2003-12-05 2012-05-15 Dainippon Sumitomo Pharma Co AGENTS FOR TREATING OR PREVENTING ischemic neuropathy
US20160185745A1 (en) * 2013-08-07 2016-06-30 Board Of Regents, The University Of Texas System Analogs of vinaxanthone and xanthofulvin, methods of synthesis, and methods of treatments thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts 114(19):181059s *

Also Published As

Publication number Publication date
GB9319494D0 (en) 1993-12-01
JPH06506202A (en) 1994-07-14
WO1992016517A1 (en) 1992-10-01
EP0580609A1 (en) 1994-02-02
GB2269382B (en) 1995-02-08

Similar Documents

Publication Publication Date Title
GB2269382A (en) Pharmaceutical xanthone derivatives
IL109144A (en) Glycoprotein IIB/IIIA inhibiting 4-pyridylamino heterocyclic derivatives process for their preparation and pharmaceutical compositions containing them
ES2182852T3 (en) PROLINAMIDE DERIVATIVES
IE894048L (en) New therapeutically active compound and a process for its¹preparation
NO944162L (en) Substituted heterocyclic carboxylic acid amides, their preparation and their use as a drug
DK0613894T3 (en) N-Heter Garyl-N'-phenylurea derivatives, preparation and use thereof
AU2323897A (en) Cyclopropyl alkanoic acid derivatives
DK394789D0 (en) HETEROCYCLIC BIPHOSPHONIC ACID DERIVATIVE, PROCEDURES FOR PREPARING THEREOF AND PHARMACEUTICAL PREPARATION CONTAINING SUCH A CONNECTION
MX9706605A (en) Indole derivatives as eaa antagonists.
NO178336C (en) Analogous Process for Preparing a Therapeutically Active Benzimidazole Compound and Intermediates
GR920100570A (en) 3(2h)-pyridazinone derivatives and process for the preparation thereof.
AU2001272761A1 (en) Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products
JPS6425776A (en) Piperidine derivative
HU9300202D0 (en) Benzo-pyrane derivatives, pharmaceutical preparatives containing them as active substance as well as method for producing them
DK0625153T3 (en) New isoindolinone derivative, its preparation and pharmaceutical preparations containing them
GB2280439A (en) CD4 binding agents and inhibitors of collagenase and protein kinase C
FI893677A (en) Process for the preparation of therapeutically useful 6-fluoro-3,5-dihydroxycarboxylic acids and their derivatives
AU4732096A (en) Remedy for pulmonary heart
NZ218121A (en) ((((3 pyridinyl)methylen aminooxy alkanoic acids, esters and pharmaceutical compositions
AU640063B2 (en) Pyridyl derivatives
AU1466592A (en) Gem-diphosphonic acid nitrosocarbamoyl derivatives, a process for the preparation thereof and pharmaceutical compositions containing them
AU7586191A (en) Hydroxyproline derivative, a process for the preparation thereof and pharmaceutical compositions containing it

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20000323